Potential of endogenous estrogen receptor β to influence the selective ER modulator ERβ complex

International Journal of Oncology

Volumn 27, Issue 2, 2005, Pages 327-335

  Chen, Bin ^a   Gajdos, Csaba ^a   Dardes, Rita ^a   Kidwai, Noman ^a   Johnston, Stephen R D ^b   Dowsett, Mitchell ^c   Craig Jordan, V ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

^b Department of Medicine ^*  (United Kingdom)

^c ROYAL MARSDEN HOSPITAL   (United Kingdom)

Author keywords

Estrogen receptor ; Real time RT PCR; SERMs; Splice variant; Tam stimulated growth

Indexed keywords

COMPLEMENTARY DNA; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; MESSENGER RNA; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN;

ANIMAL; ARTICLE; BAGG ALBINO MOUSE; BREAST TUMOR; CELL PROLIFERATION; CHEMISTRY; COMPARATIVE STUDY; DNA SEQUENCE; DRUG EFFECT; DRUG RESISTANCE; DRUG SCREENING; EXPERIMENTAL NEOPLASM; FEMALE; GENE EXPRESSION REGULATION; GENETIC TRANSFECTION; GENETICS; HUMAN; METABOLISM; METHODOLOGY; MISSENSE MUTATION; MOUSE; NUDE MOUSE; OVARIECTOMY; PATHOLOGY; REPRODUCIBILITY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL LINE;

ANIMALS; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; DNA, COMPLEMENTARY; DRUG RESISTANCE, NEOPLASM; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, INBRED BALB C; MICE, NUDE; MUTATION, MISSENSE; OVARIECTOMY; RALOXIFENE; REPRODUCIBILITY OF RESULTS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SELECTIVE ESTROGEN RECEPTOR MODULATORS; SEQUENCE ANALYSIS, DNA; TAMOXIFEN; TRANSFECTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 32044470341     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.27.2.327     Document Type: Article

References (44)

1. Jensen EV and Jacobson HI: Basic guides to the mechanism of estrogen action. Recent Prog Horm Res 18: 387-414. 1962.
2. Jensen EV. Greene GL. Closs LE. De Sombre ER and Nadji M: Receptors reconsidered: a 20-year perspective. Recent Prog Horm Res 38: 1-40. 1982.
3. Walter P. Green S. Greene G. Krust A. Bonert JM. Jeltsch JM. Staub A. Jensen E. Scrace G. Waterfield M. et al: Cloning of the human estrogen receptor cDNA. Proc Natl Acad Sci USA 82: 7889-7893. 1985.
4. Greene GL. Gilna P. Waterfield M. Baker A. Hort Y and Shine J: Sequence and expression of human estrogen receptor complementary DNA. Science 231: 1150-1154. 1986.
5. Green S. Waller P. Kumar V. Krust A. Bonert JM. Argos P and Chambon P: Human oestrogen receptor cDNA: sequence, expression and homology to v-erB-A. Nature 320: 134-139. 1986.
6. Jensen EV. Block GE. Smith S. Kyser K and De Sombre ER: 26. Estrogen receptors and breast cancer response to adrenalectomy. Natl Cancer Inst Monogr. 34: 55-70. 1971. 27.
7. McGuire WL. Carbone PP and Volliner EP: Estrogen Receptors in Human Breast Cancer. Raven Press, New York. 1975.
8. EBCTCG: Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet 351: 1451-1467. 1998. 28.
9. Levenson AS and Jordan VC: Selective oestrogen receptor modulation: molecular pharmacology for the millennium. Eur J Cancer 35: 1628-1639. 1999. 29.
10. Jensen EV and Jordan VC: The estrogen receptor: a model for molecular medicine. Clin Cancer Res 9: 1980-1989. 2003.
11. Kuiper GG. Enmark E. Pelto-Huikko M. Nilsson S and Guslafsson JA: Cloning of a novel receptor expressed in rat 30. prostate and ovary. Proc Natl Acad Sci USA 93: 5925-5930. 1996.
12. Mossclman S. Polman J and Dijkcma R: ER beta: identification and characterization of a novel human estrogen receptor. FEBS 31. Lett 392:49-53. 1996.
13. Jordan VC. Gapstur S and Morrow M: Selective estrogen receptor modulation and reduction in risk of breast cancer, osteoporosis, and coronary heart disease. J Natl Cancer Inst 93: 1449-1457.2001. 32.
14. Katzenellenbogen JA. O'Malley BW and Katzenellenbogen BS: Tripartite steroid hormone receptor pharmacology: interaction with multiple effector sites as a basis for the cell-and promoter-33. specific action of these hormones. Mol Endocrinol It): 119-131. 1996.
15. Cowley SM. Hoare S, Mossclman S and Parker MG: Esirogen receptors alpha and beta form heterodimers on DNA. J Biol 34. Chem 272: 19858-19862. 1997.
16. Hall JM and McDonnell DP: The estrogen receptor beta-isoform (ERBeta) of the human estrogen receptor modulates ERalpha transcriptional activity and is a key regulator of the cellular response to estrogens and antiestrogens. Endocrinology 140: 35. 5566-5578. 1999.
17. Webb P. Nguyen P. Valentine C. Lopez GN. Kwok GR. Melnemey E. Katzenellenbogen BS, Enmark E. Guslafsson JA. Nilsson S and Kushner PJ: The estrogen receptor enhances AP-I activity by two distinct mechanisms with different 36. requirements for receptor transactivation functions. Mol Endocrinol 13: 1672-1685. 1999.
18. Speirs V, Malone C. Walton DS. Kerin MJ and Atkin SL: Increased expression of estrogen receptor beta mRNA in 37. tamoxifen-resistant breast cancer patients. Cancer Res 59: 5421-5424. 1999.
19. Dotzlaw H. Leygue E. Watson PH and Murphy LC: Estrogen receptor-beta messenger RNA expression in human breast tumor biopsies: relationship to steroid receptor status and 38. regulation by progeslins. Cancer Res 59: 529-532. 1999.
20. Vladusic EA. Hornby AE. Guerra-Vladusic FK and Lupu R: Expression of estrogen receptor beta messenger RNA variant in 39. breast cancer. Cancer Res 58: 210-214. 1998.
21. Vladusic EA. Hornby AE. Guerra-Vladusic FK. Lukins J and Lupu R: Expression and regulation of estrogen receptor beta 40. in human breast tumors and cell lines. Oncol Rep 7: 157-167. 2000.
22. MacGregor Schafer J, Liu H, Bentrem DJ. Zapf JW and Jordan VC: Allosteric silencing of activating function I in the 41. 4-hydroxytamoxifen estrogen receptor complex is induced by substituting glycine for aspartate at amino acid 351. Cancer Res 42. 60: 5097-5105. 2000.
23. Liu H. Lee ES. Deb Los Reyes A. Zapf JW and Jordan VC: Silencing and reactivation of the selective estrogen receptor modulator-estrogen receptor alpha complex. Cancer Res 61: 3632-3639.2001. 43.
24. Liu H. Park WC. Bentrem DJ. McKian KP. Reyes Ade L. Loweth JA. Schafer JM. Zapf JW and Jordan VC: Structure-function relationships of the raloxifene-estrogen receptor-alpha complex for regulating transforming growth factor-alpha expression in breast cancer cells. J Biol Chem 277: 9189-9198. 44. 2002.
25. Heid CA. Stevens J. Livak KJ and Williams PM: Real time quantitative PCR. Genome Res 6: 986-994. 1996.
26. Gibson UE. Heid CA and Williams PM: A novel method for real time quantitative RT-PCR. Genome Res 6: 995-1001. 1996.
27. Jiang SY and Jordan VC: Growth regulation of estrogen receptor-negative breast cancer cells transfected with complementary DNAs for estrogen receptor. J Nail Cancer Inst 84: 580-591. 1992.
28. Catherino WH. Wolf DM and Jordan VC: A naturally occurring estrogen receptor mutation results in increased estrogenicity of a tamoxifen analog. Mol Endocrinol 9: 1053-1063. 1995.
29. Gotlardis MM. Robinson SP and Jordan VC: Estradiol-stimulated growth of MCF-7 tumors implanted in athymic mice: a model to study the tumoristatic action of tamoxifen. J Steroid Biochem 30: 311-314. 1988.
30. Yao K. Lee ES. Bentrem DJ. England G. Schafer JI. O'Regan RM and Jordan VC: Antitumor action of physiological estradiol on tamoxifen-stimulated breast tumors grown in athymic mice. Clin Cancer Res 6: 2028-2036. 2(XX).
31. Satysawaroop PG. Zaino RJ and Mortel R: Hormonal control of growth of human endometrial carcinoma in nude mouse model. In: Progress in Cancer Research and Therapy. Bresciani F. King RJB, Lippman M and Raynaud J-P (eds). Raven Press. Ltd-New York. pp430-435. 1988.
32. Clarke CL and Satyaswaroop PG: Photoaffinity labeling of the progesterone receptor from human endometrial carcinoma. Cancer Res 45: 5417-5420. 1985.
33. Robinson SP and Jordan VC: Antiestrogenic action of toremifene on hormone-dependent, -independent, and heterogeneous breast tumor growth in the athymic mouse. Cancer Res 49: 1758-1762, 1989.
34. O'Regan RM. Cisneros A. England GM. MacGregor JI. Muenzner HD. Assikis VJ. Bilimoria MM. Piette M. Dragan YP. Pitot HC. Chatterton R and Jordan VC: Effects of the anti-estrogens tamoxifen, toremifene. and ICI 182.780 on endometrial cancer growth. J Natl Cancer Inst 90: 1552-1558. 1998.
35. Inoue S. Ogawa S. Horie K. Hoshino S. Goto W. Hosoi T. Tsutsumi O. Muramalsu M and Ouchi Y: An estrogen receptor beta isoform that lacks exon 5 has dominant negative activity on both ERalpha and ERBcta. Biochem Biophys Res Commun 279: 814-819. 2(XX).
36. Moore JT. McKee DD. Slentz-Kesler K. Moore LB. Jones SA. Horne EL. Su J L. Kliewer SA. Lehmann JM and Willson TM: Cloning and characterization of human estrogen receptor beta isoforms. Biochem Biophys Res Commun 247: 75-78. 1998.
37. Ogawa S. Inoue S. Watanabe T. Orimo A. Hosoi T. Ouchi Y and Muramalsu M: Molecular cloning and characterization of human estrogen receptor betaex: a potential inhibitor of esirogen action in human. Nucleic Acids Res 26: 3505-3512. 1998.
38. Levenson AS and Jordan VC: The key to the antiestrogenic mechanism of raloxifene is amino acid 351 (aspartate) in the estrogen receptor. Cancer Res 58: 1872-1875. 1998.
39. Jones PS. Parrott E and White IN: Activation of transcription by estrogen receptor alpha and beta is cell type-and promoter-dependent. J Biol Chem 274: 32008-32014. 1999.
40. Paech K. Webb P, Kuiper GG, Nilsson S. Gustafsson J. Kushner PJ and Scanlan TS: Differential ligand activation of estrogen receptors ERalpha and ERBeta at API sites. Science 277: 1508-1510. 1997.
41. Hedden A. Muller V and Jensen EV: A new interpretation of anticstrogen action. Ann NY Acad Sci 761: 109-120, 1995.
42. Newman SP. Bates NP. Vemimmen D. Parker MG and Hurst HC: Cofactor competition between the ligand-bound oestrogen receptor and an intron I enhancer leads to oestrogen repression of ERBB2 expression in breast cancer. Oncogene 19: 490-497, 2000.
43. Osborne CK. Banlou V. Hopp TA. Chamness GC. Hilsenbeek SG. Fuqua SA. Wong J. Allred DC. Clark GM and Schiff R: Role of the estrogen receptor coactivalor AIBI (SRC-3) and HER-2/neu in tamoxifen resistance in breast cancer. J Natl Cancer Inst 95: 353-361.2003.
44. Font De Mora JBM: AIBI is a conduit for kinase-mediated growth factor signaling to the estrogen receptor. Mol Cell Biol 20: 5041-5047. 2000.